Ensysce Biosciences Expands Global Opioid Patent Portfolio

~ TAAP^™ and MPAR^® technologies extended across opioid products to advance safer pain treatment ~

SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 21, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today announced it received a Notice of Allowance from the Brazilian Patent Office for the issuance of a patent* covering additional opioid families, utilizing the Company's proprietary TAAP (Trypsin Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance) technologies.

The newly allowed patent includes both composition of matter and method of use claims, further strengthening Ensysce's intellectual property estate and expanding its global protection for Next Generation analgesics. This patent builds on the protection Ensysce has around additional opioid families not only in North America but also in the EU and South America.

"Applying MPAR technology across all TAAP-designed opioids has the potential to significantly reduce abuse and, importantly, help prevent overdose," said Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences. "This represents a meaningful advancement in patient safety without compromising pain relief."

"We continue to expand our intellectual property footprint to support the global development of safer, more effective therapies," said Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences. "This patent strengthens our pain portfolio program and underscores the transformative potential of our TAAP and MPAR platforms. Together with our recently announced patent allowance covering ADHD and opioid use disorder products, this progress moves us closer to a future in which patients can be treated effectively without the devastating consequences of misuse or overdose."

* ‘Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids' Brazil Patent No. PI0919711-7

About Ensysce Biosciences

Ensysce Biosciences is a clinical stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP^TM) and Multi-Pill Abuse Resistance (MPAR) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.